Dario N. R. Carrara
Vorstandsvorsitzender bei Amzell Ltd.
Aktive Positionen von Dario N. R. Carrara
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Amzell Ltd.
Amzell Ltd. Pharmaceuticals: MajorHealth Technology Amzell Ltd. is a Dutch virtual development pharmaceutical company that specializes in taking candidate or repurposed drugs and devices through to proof of concept or registration for sale to commercial healthcare companies. The private company is based in Hoofddorp, Netherlands, and has subsidiaries in Switzerland. The company focuses on developing well-characterized active substances using innovative platform drug delivery technologies to provide more effective drug delivery, increased efficacy, and improved safety and compliance. One of their products, AMZ001, is a non-invasive topical gel formulation containing 3.06%% diclofenac sodium, which is a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain related to knee osteoarthritis. The CEO of the company is Dario N. R. Carrara. | Vorstandsvorsitzender | - | - |
Karriereverlauf von Dario N. R. Carrara
Ehemalige bekannte Positionen von Dario N. R. Carrara
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
ANTARES PHARMA, INC. | Corporate Officer/Principal | 01.01.1995 | 31.12.2010 |
Antares Pharma AG
Antares Pharma AG Pharmaceuticals: OtherHealth Technology Part of Halozyme Therapeutics, Inc., Antares Pharma AG manufactures and develops gel and patch technologies for use in hormone replacement therapy. Antares Pharma was acquired by Antares Pharma, Inc., a subsidiary of Halozyme Therapeutics, Inc. from Permatec Holding AG on February 01, 2001 for $13.23 million. | Corporate Officer/Principal | 01.01.2000 | 01.01.2000 |
Laboratorios Beta SA
Laboratorios Beta SA Pharmaceuticals: MajorHealth Technology Laboratorios Beta SA is an Argentinean pharmaceutical company that specializes in the manufacturing and wholesale of anti-inflammatory and anti-rheumatic drugs. The private company is based in Buenos Aires, Argentina. | Corporate Officer/Principal | 01.01.1995 | 01.01.1995 |
Ausbildung von Dario N. R. Carrara
Universidad de Buenos Aires | Doctorate Degree |
Statistik
International
Argentinien | 3 |
Vereinigte Staaten | 2 |
Schweiz | 2 |
Operativ
Corporate Officer/Principal | 3 |
Doctorate Degree | 1 |
Chief Executive Officer | 1 |
Sektoral
Health Technology | 5 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 4 |
---|---|
Antares Pharma, Inc.
Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
Antares Pharma AG
Antares Pharma AG Pharmaceuticals: OtherHealth Technology Part of Halozyme Therapeutics, Inc., Antares Pharma AG manufactures and develops gel and patch technologies for use in hormone replacement therapy. Antares Pharma was acquired by Antares Pharma, Inc., a subsidiary of Halozyme Therapeutics, Inc. from Permatec Holding AG on February 01, 2001 for $13.23 million. | Health Technology |
Laboratorios Beta SA
Laboratorios Beta SA Pharmaceuticals: MajorHealth Technology Laboratorios Beta SA is an Argentinean pharmaceutical company that specializes in the manufacturing and wholesale of anti-inflammatory and anti-rheumatic drugs. The private company is based in Buenos Aires, Argentina. | Health Technology |
Amzell Ltd.
Amzell Ltd. Pharmaceuticals: MajorHealth Technology Amzell Ltd. is a Dutch virtual development pharmaceutical company that specializes in taking candidate or repurposed drugs and devices through to proof of concept or registration for sale to commercial healthcare companies. The private company is based in Hoofddorp, Netherlands, and has subsidiaries in Switzerland. The company focuses on developing well-characterized active substances using innovative platform drug delivery technologies to provide more effective drug delivery, increased efficacy, and improved safety and compliance. One of their products, AMZ001, is a non-invasive topical gel formulation containing 3.06%% diclofenac sodium, which is a nonsteroidal anti-inflammatory drug (NSAID) used for the treatment of pain related to knee osteoarthritis. The CEO of the company is Dario N. R. Carrara. | Health Technology |
- Börse
- Insiders
- Dario N. R. Carrara
- Erfahrung